Takeda Pharmaceutical Company Limited Deal History & Licensing Activity
Takeda Pharmaceutical Company Limited is a large pharma headquartered in Japan. Over the past three years, Takeda Pharmaceutical Company Limited has been involved in 6 licensing and acquisition transactions, with a primary focus on Small Molecules (4 deals). The company currently has 50 active clinical trials, primarily in Autoimmune.
Deals (12mo)
3
Active Trials
50
Top Modality
Small Molecules
Focus Area
Autoimmune
Takeda Pharmaceutical Company Limited Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Takeda Pharmaceutical Company Limited in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| olverembatinib | Takeda | Small Molecules | Unknown | license | May 20, 2026 |
| Gamma delta T-cell platform | Takeda | Cell Therapy | Preclinical | option | May 19, 2026 |
| olverembatinib | Takeda | Small Molecules | Phase 3 |
Takeda Pharmaceutical Company Limited Pipeline Focus
Therapeutic areas and modalities where Takeda Pharmaceutical Company Limited is most active based on deal history and clinical trial data.
Therapeutic Areas
Takeda Pharmaceutical Company Limited Clinical Pipeline
Takeda Pharmaceutical Company Limited has 50 active clinical trials across 5 development phases.
20
Unknown
1
Not Applicable
3
Phase 1
12
Phase 2
14
Phase 3
See How Your Asset Matches Takeda Pharmaceutical Company Limited's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Autoimmune assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Cell Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for cell therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Takeda Pharmaceutical Company Limited Licensing & Deal Activity
Takeda Pharmaceutical Company Limited is a large pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 6 deals over the past three years, Takeda Pharmaceutical Company Limited ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Takeda Pharmaceutical Company Limited include Autoimmune (13 deals and trials), Oncology (6 deals and trials), Solid Tumors (6 deals and trials), and CNS Disorders (6 deals and trials). In terms of modality, Takeda Pharmaceutical Company Limited has shown particular interest in small molecules, cell therapy, antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Takeda Pharmaceutical Company Limited and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Takeda Pharmaceutical Company Limited's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.